Immune Defense Beyond Binding: Study Reveals Mechanical Stability Is Key to Neutralizing SARS-CoV-2 Variants

International researchers identify mechanical stability as a critical factor in antibody effectiveness, providing a new blueprint for viral and cancer therapies.

By: AXL Media

Published: Apr 30, 2026, 8:22 AM EDT

Source: Information for this report was sourced from EurekAlert!

Evaluating the Mechanical Resilience of the Immune System

For years, the gold standard for measuring an antibody's effectiveness has been its binding affinity—essentially, how tightly it can latch onto a virus to prevent infection. However, a new study led by Dr. Adolfo Poma at the Institute of Fundamental Technological Research, Polish Academy of Sciences (IPPT PAN), suggests this view is incomplete. In the human body, antibodies do not operate in a static environment; they are subjected to constant mechanical forces from blood flow, lung movement, and cellular interactions. The research, published in Physical Chemistry Chemical Physics, highlights that "mechanical stability" is a previously overlooked factor that determines whether an antibody-virus complex stays intact or is pulled apart by physiological stress.

Mapping Force Distribution in Y-Shaped Antibodies

The research team used high-performance computer simulations to analyze how different SARS-CoV-2 variants, including the original strain and Omicron subvariants like BA.4 and JN.1, interact with antibodies under pressure. The results showed that conventional Y-shaped antibodies manage mechanical loads through a specialized division of labor. The heavy chain bears the brunt of the physical force, while the light chain acts as a structural stabilizer. Together, these components form a cooperative unit capable of resisting forces up to 500 piconewtons. The study proved that the intact structure is significantly stronger than its parts; removing either chain causes the entire defense mechanism to lose its mechanical integrity.

Nanobodies vs. Conventional Antibodies

The team also compared traditional antibodies with nanobodies—smaller, single-domain proteins derived from camelids like llamas. While nanobodies are prized for their compact size and stability, the study found that traditional antibodies benefit from having two binding arms, which allows for a more complex and resilient structural response to force. This comparison provides valuable data for bioengineers deciding between these two frameworks for drug development, emphasizing that the "strong core" of a multi-chain antibody may offer superior performance in high-pressure biological environments compared to more simplified protein designs.